SLXN · Silexion Therapeutics Corp
$0.41
-0.01 (-1.45%)
At close · Aug 17
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“management has concluded that there is substantial doubt about the Company's ability to continue as a going concern, as management believes its current funds will be sufficient to fund its operations for only several months from the date these financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.34M
Shares
5.56M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ilan Hadar | Chief Executive Officer (formerly Managing Director of Silexion Israel) | $1,540,628 |
| Dr. Mitchell Shirvan | Chief Scientific and Development Officer | $1,301,490 |
| Mirit Horenshtein Hadar | Chief Financial Officer (formerly EVP Finance of Silexion Israel) | $770,090 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Ilan Hadar | Chief Executive Officer (formerly Managing Director of Silexion Israel) | $253,614 |
| Dr. Mitchell Shirvan | Chief Scientific and Development Officer | $206,800 |
| Mirit Horenshtein Hadar | Chief Financial Officer (formerly EVP Finance of Silexion Israel) | $26,238 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Professor Amnon Peled | member of the Board | Resigned | 2026-07-31 |
| Ilan Levin | member of the Board | Terminated | 2026-03-25 |
| Professor Amnon Peled | independent director | Appointed | 2024-12-10 |
| Ilan Shiloah | independent director | Resigned | 2024-09-19 |